verified SJR 0,554 · Q2 • database Scopus / SJR indexed

Saudi Arabia · Wolters Kluwer Health

workspace_premium Q2 — Medicine (miscellaneous) visibility_off Double blind peer review lock_open Open Access

Hematology/Oncology and Stem Cell Therapy

Hematology/Oncology and Stem Cell Therapy is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 31. It is an CC BY-NC-ND Journal with a Double blind peer review review system The scope of the journal is focused on haematology, oncology, hematopoietic stem cell therapy. It has an SJR impact factor of 0,554 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,554.

ISSN: 1658-3876

Publisher: Wolters Kluwer Health

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,554 Q2

H-index 31

Acceptance rate pie_chart

38%

Source Acceptance_Rate

Time to publication hourglass_top

27 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

NPD Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR

SJR Impact

0,554

H-index

Docs (year)

Docs 3y

152

Total refs

529

Cites 3y

258

Citable 3y

143

Cites/Doc 2y

1.5

Ref/Doc

17.06

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Corpus callosum lymphoma

Yield of computed tomography pulmonary angiogram in the emergency department in cancer patients suspected to have pulmonary embolism

Dengue fever causing febrile neutropenia in children with acute lymphoblastic leukemia: An unknown entity

Dengue fever as a cause of febrile neutropenia in adult acute lymphoblastic leukemia: A single center experience

Cyclosporine-related posterior reversible encephalopathy syndrome after cord blood stem cell transplantation

CXCR4 (CD184) expression on stem cell harvest and CD34 + cells post-transplant

Cutaneous light chain amyloidosis with multiple myeloma: A concise review

Current indication for hematopoietic cell transplantation in adults

Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer

Current concepts on hematopoietic stem cell transplantation outcome registries; Emphases on resource requirements for new registries

Could the mosaic pattern of chromosomal abnormality predict overall survival of patients with myelodysplastic syndrome?

Cost and quality issues in establishing hematopoietic cell transplant program in developing countries

SHOW MORE ARTICLES

Corrigendum to 'Use of Octreotide for relief of gastro-intestinal (GI) symptoms in systemic mastocytosis' [Hematology/Oncology and Stem Cell Therapy 6/2 (2013) 72-75]

A rare case of familial multiple subcutaneous lipomatosis with novel PALB2 mutation and increased predilection to cancers

Composite angioimmunoblastic T-cell and diffuse large B-cell lymphoma

Complications of hematopoietic stem cell transplantation: Bacterial infections

Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response

Blastic plasmacytoid dendritic cell neoplasm: A rare subtype of myeloid leukemia

Bizarre multilobated myeloma cells mimicking megakaryocytes

BCL-2 overexpression overcomes cell of origin stratification in diffuse large B-cell lymphoma

Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients

Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma

Alveolar rhabdomyosarcoma masquerading as Burkitt's lymphoma in bone marrow

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia - A case report

FAQs

Hematology/Oncology and Stem Cell Therapy has an SJR of 0,554 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Hematology/Oncology and Stem Cell Therapy is 38%.

Hematology/Oncology and Stem Cell Therapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Hematology/Oncology and Stem Cell Therapy?

What is the APC / publication cost?

What is the acceptance rate?